Expression of STC2 protein in endometrial cancer and its relationship with prognosis

ObjectiveTo investigate the expression levels of stanniocalcin-2(STC2) protein in endometrial cancer and its relationship with prognosis.

MethodsA total of 78 samples of endometrial cancer were collected.The expression level of STC2 protein in all cases were measured using immunohistochemistry, and the correlation of which with clinical characteristics was analyzed.The relationship between STC2 expression level and relapse-free survival rate was compared.

ResultsThe results of immunohistochemistry showed that the tumor cells with positive STC2 staining in 61 samples were found, which accounted for 65.38%.Based on staining score system, the non-or low-expression of STC2 in 35 samples(44.87%) and high-expression of STC2 in 43 samples (55.13%) were identified.There was no statistical significance in the age between two groups(P>0.05), but the FIGO staging, lymphatic vascular invasion, myometrium invasion and cervical involvement in high-expression group significantly aggravated compared with the non-expression and low-expression group, and the difference of which was statistically significant(P < 0.05 to P < 0.01).All patients were followed up for 12 months.During the following-up, the tumor recurrence in 14 cases(17.95%) found, which included 2 cases(5.71%) in non-or low-expression group and 12 cases(27.91%) in high-expression group.The relapse-free survival rate in high-expression group was lower than that in non-or low-expression group(P < 0.05).

ConclusionsThere is light-moderate STC2 expression in most cases of endometrial cancer, and its high expression level is associated with the poor prognosis.STC2 may be a prediction marker for the prognosis of endometrial cancer.